Is the gold rush in immunotherapy trials good?
Developing a unique strategy backed by a strong scientific background, robust preclinical and early phase clinical data, and well-designed clinical trials will go a long way in this crowded race.
Andy Kinley
Andy Kinley, PhD, is Senior Director, Oncology Strategy of Novella Clinical where he provides strategic guidance to the oncology and operational teams, as well as consultative oversight for biopharma, sponsors developing cancer therapeutics. He has more than 15 years of experience in oncology research and is focused on leveraging the massive amounts of emerging clinical research data to guide biopharma sponsors with the development of their oncology and immuno-oncology programs. He holds a PhD in Microbiology with a focus in cancer cell signaling from the University of Virginia.